# SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

> **NCT07662811** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 396 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SYHX2011
- **DRUG:** Carboplatin
- **DRUG:** Enlonstobart
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07662811
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662811, "SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*